Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
REV3L	rs240993	TT	adalimumab	efficacy	no	Response was based on the change in PASI score before and after 3 months of treatment. PASI = psoriasis area and severity index.	Genotype TT is not associated with response to adalimumab in people with Psoriasis as compared to genotype CC.	27564082	1448264037
REV3L	rs3218592	T	capecitabine	efficacy	no	pfSNP identified 2800 SNPS associated with key-words: 5-FU, capecitabine and oxilaplatin and colorectal cancer. Various criteria were used to determine 1536 SNPs to genotype. These SNPs were genotyped in a discovery cohort (N=62) and tested in a validation cohort (N=27). Both cohorts consisted of patients with colorectal cancer metastasis in liver. Three non-responder SNPs combined with any one of three SNPs in LD in the UMPS gene (rs2291078 A, rs3772809 G, rs3772810 G) account for 37.5% of all patients that were classified as non-responders to capecitabine/fluorouracil therapy. Combined multivariate collapsing analyses revealed a statistical significance between those SNPs and the "non-responder" phenotype.	Allele T is associated with decreased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele C.	25372392	1185002413
REV3L	rs465646	AG + GG	cisplatin	efficacy	no	This SNP not significantly associated with event-free survival (p = 0.601) or overall survival (p = 0.335), as determined by recurrence or death, with mean follow-up time of 143 months.	Genotypes AG + GG are not associated with increased response to cisplatin in people with Osteosarcoma as compared to genotype AA.	25748439	1447675769
REV3L	rs462779	AG + GG	cisplatin	efficacy	yes	Outcomes measured as event-free survival (p=0.056) and overall survival (p=0.018). Manuscript gives alleles as T and C.	Genotypes AG + GG are associated with decreased response to cisplatin in people with Osteosarcoma as compared to genotype AA.	25748439	1447675725
REV3L	rs240993	TT	etanercept	efficacy	no	Response was based on the change in PASI score before and after 3 months of treatment. PASI = psoriasis area and severity index.	Genotype TT is not associated with response to etanercept in people with Psoriasis as compared to genotype CC.	27564082	1448264031
REV3L	rs240993	TT	ustekinumab	efficacy	no	Response was based on the change in PASI score before and after 3 months of treatment. PASI = psoriasis area and severity index.	Genotype TT is not associated with response to ustekinumab in people with Psoriasis as compared to genotype CC.	27564082	1448264043
REV3L	rs3204953	CT + TT	cisplatin	efficacy	no	This SNP is not associated with event-free survival (p = 0.998) or overall survival (p = 0.265), as determined by recurrence or death, with mean follow-up time of 143 months.	Genotypes CT + TT are not associated with increased response to cisplatin in people with Osteosarcoma as compared to genotype CC.	25748439	1447675754